| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
RAPID COMMUNICATION |
a Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel;
b The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Key Words. ES cells • Pancreatic differention • Insulin-secreting cells • Differentiation
Correspondence:
Joseph Itskovitz-Eldor, M.D., Department of Obstetrics and Gynecology, Rambam Medical Center, P.O.B. 9602, Haifa 31096, Israel. Telephone: 972-4-854-2536; Fax: 972-4-854-2503; e-mail: Itskovitz{at}rambam.health.gov.il
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
We present here a method for forming immature islet-like clusters of insulin-producing cells derived from hES cells.
The protocol consisted of several steps. Embryoid bodies were first cultured and plated in insulin-transferrin-selenium-fibronectin medium, followed by medium supplemented with N2, B27, and basic fibroblast growth factor (bFGF). Next, the glucose concentration in the medium was lowered, bFGF was withdrawn, and nicotinamide was added. Dissociating the cells and growing them in suspension resulted in the formation of clusters which exhibited higher insulin secretion and had longer durability than cells grown as monolayers.
Reverse transcription-polymerase chain reaction detected an enhanced expression of pancreatic genes in the differentiated cells. Immunofluorescence and in situ hybridization analyses revealed a high percentage of insulin-expressing cells in the clusters. In addition to insulin, most cells also coexpressed glucagon or somatostatin, indicating a similarity to immature pancreatic cells.
Further improvement of this insulin-producing cell protocol may lead to the formation of an unlimited source of cells suitable for transplantation.
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
Diabetes mellitus is a major health problem affecting more than 5% of the global population and is the most common metabolic disorder [5]. Diabetes mellitus takes two forms: type I (insulin-dependent), caused by an autoimmune destruction of the insulin-producing ß cells and type II (non-insulin-dependent), resulting from a combination of reduced insulin sensitivity and impaired function of the insulin-secreting ß cells. The present treatments for diabetes do not offer a cure and do not prevent the secondary complications associated with diabetes, such as diabetic retinopathy, nephropathy, and neuropathy [6]. Early treatment of these patients and restoration of the ß-cell function through pancreas or islets transplantation can both free the patients from their dependency on insulin and prevent complications [7–9]. However, one of the major obstacles in human transplantation is the limited supply of donor tissue [10].
It has previously been shown that hES cells can spontaneously differentiate into insulin-producing cells, can secrete insulin, and can express other ß-cell markers [11, 12]. Research conducted on mouse embryonic stem cells led to insulin-producing cells [13–16], which were capable of curing diabetes in streptozotocin-treated mice [13, 14, 16, 17]. Here we show that hES cells can be induced to form islet-like clusters similar to immature pancreatic ß cells and to produce insulin.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
In Vitro Differentiation Procedure Undifferentiated hES cells were grown on mitotically inactivated mouse embryonic fibroblast in 80% knockout Dulbecco’s modified Eagle’s medium (DMEM), 20% knockout serum replacement, 1 mM glutamine, 1% nonessential amino acid, 0.1 mM 2-mercaptoethanol, and 4 ng/ml basic fibroblast growth factor (bFGF) (all from GIBCO Invitrogen; Paisley, UK) (stage 1). They were then dissociated by applying 1 mg/ml type IV collagenase (GIBCO Invitrogen). Thirty minutes later, the cells were scraped with a 5-ml pipette and transferred into plastic petri dishes (Miniplast; Ein-Shemer, Israel) to allow their aggregation. The resultant EBs (stage 2) were cultured for 7 days in 80% knockout DMEM (GIBCO Invitrogen), 20% defined fetal bovine serum (Hyclone; Logan, UT), 1 mM glutamine, and 1% nonessential amino acid (both from GIBCO Invitrogen), with a change of medium every 3 days.
Seven-day-old EBs (which consisted of 10,000 cells, on average) were plated at a density of 300 EBs per well in six-well plastic culture plates (Nunc; Roskilde, Denmark) and grown for an additional week in medium I: DMEM (DMEM)/F12 1:1, insulin (10 mg/l)-transferrin (6.7 ng/l)-selenium (ITS) (5.5 mg/l), and 1 mM glutamine (all from GIBCO Invitrogen) with a supplement of 5 µg/ml fibronectin (Roche Diagnostics GmbH; Mannheim, Germany) (stage 3). After 1 week in the ITS and fibronectin (ITSF) medium, the cells were dissociated by trypsin-EDTA (Biological Industries; Beit Haemek, Israel) to single cells and plated on plastic tissue-culture plates at a concentration of 2 x 105/ml in medium II: DMEM/F12 1:1 with N2 supplement (500 µg/ml insulin, 10,000 µg/ml transferrin, 0.63 µg/ml progesterone, 1,611 µg/ml putrascine, and 0.52 µg/ml selenite), B27 media (both from GIBCO Invitrogen), according to manufacturer’s instructions, 1 mM glutamine, and 10 ng/ml bFGF (GIBCO Invitrogen). Before plating, the tissue-culture plates were coated with either 0.1% gelatin or poly-L-ornithine (15 ng/ml) (Sigma Chemical Co.; St. Louis, MO). At this stage, clusters of cells were formed (stage 4), and these cells expanded throughout the week, with change of media every other day.
At the next stage (stage 5), bFGF was removed and 10 mM of nicotinamide (Sigma Chemical Co.; St. Louis, MO) were added. Since DMEM without glucose was used, the total glucose concentration in the medium was reduced from 3,151 to 901 mg/l (medium III thus contained DMEM/F12 1:1 with 901 mg/l glucose, supplemented with N2 and B27 media, 1 mM glutamine, and 10 mM nicotinamide). After 4 days in medium III, the forming clusters were dissociated by trypsin-EDTA, and they continued to grow in suspension in petri dishes with medium III (stage 6).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from differentiated hES cells using Tri-Reagent (Sigma Chemical Co.), according to the manufacturer’s recommended protocol. cDNA was synthesized from 1 µg total RNA using Moloney murine leukemia virus (MMLV) reverse transcriptase RNase H minus (Promega; Madison, WI). The absence of DNA contamination in RNA samples was confirmed with PCR primers flanking an intron. Primers and the reaction conditions are described in Table 1
. The PCR products were size fractionated by 2% agarose gel electrophoresis.
|
Immunofluorescence
Stage VI clusters were seeded on 13-mm glass cover slides in six-well culture plates. Forty-eight hours after seeding, cells were fixed for 20 min in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized using 0.5% Triton X-100 in PBS/1% serum, and incubated overnight with the primary antibody mouse anti-insulin 1:100 (Sigma Chemical Co.) with either rabbit anti-C-peptide 1:100 (Linco Research Inc.; St. Charles, MI), rabbit anti-glucagon 1:100, or rabbit anti-somatostatin 1:200 (both from DAKO Corporation; Carpinteria, CA). Mouse anti-nestin 1:10 (R&D Systems Inc.; Minneapolis, MN) and mouse anti-smooth muscle actin 1:20 (DAKO Corporation) were also used with rabbit anti-C-peptide (as previously described).
After rinsing, secondary anti-rabbit immunoglobulin G (IgG) fluorescence isothiocyanate (FITC) conjugated antibody 1:100 and anti-mouse IgG indocarbocyanine (Cy3) conjugated antibody 1:100 (both from Sigma Chemical Co.) were added to the samples, which were then incubated for an additional hour. Finally, the cells were rinsed once more and mounted with mounting media (VECTASHIELD; Vector Labs; Burlingame, CA). The slides were analyzed using a confocal microscope (Bio-Rad MRC 1024; Richmond, CA).
BrdU Labeling
To determine the percentage of proliferating cells, the BrdU Streptvidin-Biotin Labeling Kit (Zymed; San Francisco, CA) was used. The cells were incubated overnight with the BrdU labeling reagent (diluted 1:100). After the incubation, cells were rinsed 2x PBS, fixed with 75% alcohol (20 min, RT), and then stained according to the manufacturer’s recommended protocol. Secondary antimouse IgG Cy3 conjugated antibody 1:100 (Sigma Chemical Co.) was added to the samples, which were then incubated for an additional hour. Finally, the nuclei of the cells were stained with TO-PRO-3 iodide 1:500 (Molecular Probes; Leiden, Netherlands) and mounted with mounting media (VECTASHIELD). The slides were analyzed using a confocal microscope (Bio-Rad MRC 1024).
TUNEL
TUNEL assay was performed to detect the amount of apoptotic cells within the clusters. Cells on glass coverslips were fixed for 20 min in 4% paraformaldehyde in PBS and then washed three times in PBS. Staining was performed using the In Situ Cell Death Detection Kit (Roche; Mannheim, Germany) according to the manufacturer’s recommended protocol. The reaction was stopped using 2XSSC buffer, washed, and then subjected to immunofluoresence staining with mouse anti-insulin (Sigma Chemical Co.).
Antisense RNA Probe for In Situ Hybridization
Antisense RNA probe was prepared from mouse insulin I (RsaI-EcoRI) cloned into pBluescript SK+ amp+, which was kindly provided by Dr. S. Efrat. Following linearization, antisense RNA was transcribed using a (T7/T3) Dig-RNA labeling kit (Roche), according to company instructions. The sense RNA probe was used as a negative control.
In Situ Hybridization Analysis
Cells were seeded on poly-L-lysine-coated slides, washed with PBS at 37°C, fixed at room temperature for 30 min in a solution of 4% weight/volume (w/v) formaldehyde, 5% (v/v) acetic acid, and 0.9% (w/v) NaCl, and washed with PBS at room temperature. Prior to in situ hybridization, cells were first dehydrated by successive incubation in 70%, 90%, and 100% ethanol; then rinsed in 100% xylene; and finally rehydrated by successive incubation in 100%, 90%, and 70% ethanol. Last, the fixed cells were incubated in PBS, treated at 37°C with pepsin (GIBCO Invitrogen) for 5 min, washed with PBS, post-fixed with 1% formaldehyde for 10 min, and washed again with PBS. Prehybridization was performed for 10 min in 2XSSC, followed by 1 hour in hybridization buffer composed of 50% formamide, 0.5 mg/ml salmon sperm DNA, 4XSSC, and 1x Denhardt’s reagent. Hybridization was conducted overnight (18 hours) at 42°C in maximal humidity with a 2- to 5-ng/µl digoxygenin-labeled probe. At the end of the incubation, slides were rinsed in SSC at increasing stringency conditions and re-rinsed with 0.1 Tris and 0.15 M NaCl, pH 7.5. Hybrids were detected by rhodamine conjugated anti-dig antibody (Roche).
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
).
|
). Decreasing the glucose concentration in the growth medium from 3,151 to 901 mg/l during stage V (as described in Materials and Methods) resulted in an increase in the insulin secretion in response to glucose, from 2.13 ± 1.32 to 8.64 ± 3.42 µu/ml per 105 cells/hour. A more dramatic increase in insulin secretion to 225.8 ± 78 µu/ml per 105 cells/hour was obtained by the formation of clusters at step VI (Fig. 1A). The time course of insulin secretion in response to glucose was further examined by incubating the cells for 5–60 min, which revealed that the amount of secreted insulin accumulated in the medium increased with time, reaching maximum effect after 60 min. To determine whether these cells use physiological signaling pathways to regulate insulin release, we examined the effect of several agonists and antagonists on insulin secretion. Incubating the cells with high glucose (16.6 mM) and 100 µM IBMX (3-isobutyl-1-methylxanthine; an inhibitor of cyclic-AMP phosphodiesterase) resulted in a small 40% increase of insulin secretion as compared with 3.3 mM glucose (Fig. 1B).
|
). These results indicate that the pancreatic machinery is used for glucose-mediated insulin release.
RT-PCR reaction, as shown in Figure 3, demonstrated an enhanced expression of pancreatic genes in the differentiating hES cells. The transcription factor, pancreatic duodenal homeobox 1 (PDX1), appeared mainly in stage III mRNA, decreased in stage IV, and reappeared in stage VI. Glucagon and neurogenine 3 (Ngn3) were highly expressed in stage III and then in stage VI. Somatostatin expression was higher at stage IV than at stage III and then disappeared. Pax4 expression increased from stage III to IV and then decreased in stage V-H (high glucose in the medium), but when the glucose concentration was reduced, Pax4 was increased (stage V-L, low glucose in the medium and stage VI). Pax6 was noticed in all stages of differentiation. The KATP-channel genes Kir6.2 and SUR1 were expressed in stages IV and in stage VI, while SUR1 was detected in stage V-L as well. Islet amyloid polypeptide (IAPP) and prohormone convertase 1/3 (PC1/3) expressions increased in stages V-L and VI. Glucokinase (GCK) was detected only in stage V-L. Insulin and other pancreatic ß-cell-specific genes, such as Nkx6.1, Is11, Glut2, and prohormone convertase 2 (PC2), were only noticed in mRNA from stage VI cells. These results indicate that differentiated cells have the ability to transcribe and process insulin.
|
). Stage VI clusters were examined by immunofluorescence for the expression of insulin, C-peptide, somatostatin, and glucagon (Fig. 5). The results revealed a high percentage of insulin- (70%), somatostatin- (43%), or glucagon (50%)-expressing cells in the clusters. The cells coexpressed both insulin and C-peptide, indicating an undeniable production of insulin. A substantial number of the cells were costained for insulin and glucagon or somatostatin, suggesting that these cells resemble immature pancreatic endocrine cells. This phenomenon has been previously described in the development of the mouse and human pancreas [20–22]. When staining the cells for the neuron marker nestin, only 10% were stained positive. Likewise, staining for the detection of smooth muscle cells resulted in only a 5% positive staining (data not shown). Similarly, RT-PCR analysis revealed that transcripts for neuronal marker NF-68KD and cardiac actin were detected only in stages IV and V-L and were absent in stage VI cells (Fig. 3).
|
|
). Furthermore, the aggregation step increased the survivability of the cells, from 1 week at stage V to over 1 month at stage VI.
|
). BrdU staining, TUNEL and C-peptide staining of the cells, confirmed that stage VI cells still proliferate and produce de novo insulin. |
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
Next, the cells were transferred to medium containing N2, B27, and bFGF. Both bFGF and keratinocyte growth factor were previously found to enhance the formation of islet-like clusters from ES cells [12, 15, 25, 26]. At the end of this stage, bFGF was withdrawn from the medium and nicotinamide was added. Nicotinamide is a poly-synthetase (ADP-ribose) inhibitor known to differentiate and increase ß-cell mass in cultured human fetal pancreatic cells [27]. This stage induces differentiation into insulin-secreting cells. Rajagopal et al. [23] claimed that the insulin secretion of the cells resulted from an uptake of insulin from the culture media, and thus challenged prior works. A recent study by Vaca et al. [28] supports our results, showing an increase of insulin secretion after cell differentiation.
The same insulin concentration in the medium was used for stages IV to VI, yet with an increase of insulin secretion. In addition, transcript for insulin was shown both by RT-PCR and in situ hybridization, along with transcripts for proinsulin and processing enzymes, PC1/3 and PC2, indicating that stage VI cells acquired the ability to synthesize and process proinsulin to mature insulin. Transcripts for the two components of the K+ATP channel, SUR1 and KIR6.2, and for Glut2 and glucokinase, which participate in signal-secretion coupling in pancreatic ß cells, were also detected. In addition, transcription factors Nkx6.1, Is11, Pax4, Pax6, Ngn3, and IAPP were also present in stage VI cells.
Somatostatin transcript was not detected beyond stage IV, although the protein was detected by immunohistochemistry in stage VI. We have found higher percentages of somatostatin-expressing cells in earlier stages (data not shown), and the staining seen in stage VI may be the result of remaining proteins. In contrast, though present in stage III and stage IV cells, only minor expression of PDX1 was observed in stage VI cells. PDX1 expression during stages III and VI may initiate a cascade of events leading to insulin transcription. Further improvement of the protocol may result in an increase in the PDX1 expression and a further increase in insulin expression and secretion.
In this study we show an improvement of the method described by Lumelsky [15], by A) reducing the glucose concentration in the last steps (medium III), and B) introducing the aggregation step, which contributes to the enrichment of insulin-producing cells and insulin secretion. The low glucose combined with nicotinamide has previously been suggested to increase the insulin content in ß cells differentiated from mouse ES cells [16, 17]. The use of a cluster phase has been previously demonstrated by Zhao et al. [29] and others [30, 31] as a useful method for long-term maintenance of human islets in vitro. Using repeated cycles of aggregation and plating of cells obtained from postmortem human islets Zhao et al. [29] were successful in maintaining the cells for 4 months without losing their potential to express insulin.
Although descriptions of the clustering technique have been made in the past, they all dealt with culturing donor islet cells in vitro. This work introduces the aggregation step, which not only increased the percentage of the insulin-expressing cells but also improved their survivability from 1 week at stage V to 1 month or more at stage VI. Different studies published on cultured human islets have described a progressive loss of insulin secretion with time [29, 32], in correlation with a poor long-term survival rate of ß cells in culture and overgrowth of fibroblastoid cells [32]. The poor long-term survival rate was explained by apoptosis and necrosis [32–36]. Using BrdU staining, TUNEL, C-peptide staining, and in situ hybridization for insulin in the clusters, we were able to confirm that stage VI cells still proliferate and produce de novo insulin. Several studies dealing with differentiation of mouse ES cells toward insulin-producing cells have shown different results of insulin secretion. Lumelsky et al. [15] reported an insulin secretion of 3 ng/mg protein after incubating the cells for 5 min with 20 mM glucose. Similar results were recently published by Moritoh et al. [37]. Blyszczuk [14] transfected mouse ES cells with Pax4 and used a differentiation protocol to reach an insulin secretion of 20 ng/mg protein after incubating the cells with either 27.7 mM glucose or 5.5 mM glucose, with the addition of 10 µM tolbutamide. Soria et al. [16] reached high insulin secretion from differentiated mouse ES that were selected by using the insulin promoter (318 ng/mg protein).
Our study demonstrates that insulin secretion obtained after aggregating the cells was more than 30-fold higher than that obtained by the monolayer cells (225.8 ± 78.5 µu/ml per 105 cells per hour after incubation with 3.3 mM glucose). The cells showed a response to the different signal pathway agonists and antagonists. IBMX, tolbutamide, and carbachol increased the secretion of insulin, whereas nifedipine inhibited it. These results indicate that pancreatic machinery is used for glucose-mediated insulin release. The responsiveness to the glucose and to the antagonists was lower than expected, possibly due to the immaturity of the cells. These results correspond with those obtained by Weinhaus et al. [38], describing poor responsiveness to glucose in fetal pancreatic ß cells. It seems that a cluster culture environment encourages cell-to-cell communication, as clustering cells share a greater surface contact area than those in monolayers. In addition to the enhanced insulin secretion after aggregating the cells, the percentage of insulin immunostaining was higher than in cells grown as monolayers (stage VI cells as compared to stage V cells).
A substantial number of the cluster cells formed in this work were costained for insulin and glucagon or somatostatin, suggesting that these cells resemble immature pancreatic embryonic cells. This phenomenon has been previously described in the development of the mouse [21] and human pancreas [20]. In the mouse embryo, cells expressing both insulin and glucagon were detected on day 9.5 [21]. Polak et al. [20] found that most 8-week-old human pancreatic cells express insulin together with glucagon and somatostatin. The percentage of cells expressing more than one marker decreased in the following weeks. One hypothesis to explain this phenomenon claimed that progenitors that transiently expressed two or more hormones gave rise to mature hormone-secreting cells [21]. Conversely, by tagging cells that expressed specific hormones with the Cre-LoxP system, it was established that double-positive progenitors do not give rise to differentiated islet cells [39]. Thus, insulin- and glucagon-expressing cells appear to rise independently during ontogeny, probably from a common precursor [39, 40].
Because of the similarities between ß cells and neuroepithelial development [41], a similar transient expression of nestin was proposed to occur in human insulin-producing ß-cell precursors [42, 43]. However, recent studies using nestin-positive cells concluded that nestin is not a specific marker of ß-cell precursors, though it may contribute to microvasculature [44, 45]. Since other reports [46] have suggested that signals from endothelial cells are critical to the growth of pancreatic endocrine cells during embryogenesis, it is possible that nestin-positive cells contribute to the developing vasculature of the pancreatic mesenchyme. Thus, the proliferation of nestin-positive cells and ß cells may be connected.
During embryogensis, cells expressing Ngn3 are the islet progenitors [47], and those Ngn+ cells give rise to the endocrine cells of the pancreas. Other reports [22] do not rule out the possibility that cells expressing glucagon, insulin, and Ngn3 together eventually become adult ß cells. Thus, the clusters produced in this work, which expressed insulin, glucagon, and Ngn3, show a resemblance to embryonic pancreatic precursor cells.
|
SUMMARY |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
|
ACKNOWLEDGMENT |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
|
FOOTNOTES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionSummaryReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. Guo and M. Hebrok Stem Cells to Pancreatic {beta}-Cells: New Sources for Diabetes Cell Therapy Endocr. Rev., May 1, 2009; 30(3): 214 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Gunawardana, R. K. P. Benninger, and D. W. Piston Subcutaneous transplantation of embryonic pancreas for correction of type 1 diabetes Am J Physiol Endocrinol Metab, February 1, 2009; 296(2): E323 - E332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Artner, Y. Hang, M. Guo, G. Gu, and R. Stein MafA is a dedicated activator of the insulin gene in vivo J. Endocrinol., August 1, 2008; 198(2): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Meier, A. E. Butler, Y. Saisho, T. Monchamp, R. Galasso, A. Bhushan, R. A. Rizza, and P. C. Butler {beta}-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of {beta}-Cell Mass in Humans Diabetes, June 1, 2008; 57(6): 1584 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, Y. Suzuki, M. Huang, F. Cao, X. Xie, A. J. Connolly, P. C. Yang, and J. C. Wu Comparison of Reporter Gene and Iron Particle Labeling for Tracking Fate of Human Embryonic Stem Cells and Differentiated Endothelial Cells in Living Subjects Stem Cells, April 1, 2008; 26(4): 864 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Serafimidis, I. Rakatzi, V. Episkopou, M. Gouti, and A. Gavalas Novel Effectors of Directed and Ngn3-Mediated Differentiation of Mouse Embryonic Stem Cells into Endocrine Pancreas Progenitors Stem Cells, January 1, 2008; 26(1): 3 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Fraker, S. Alvarez, P. Papadopoulos, J. Giraldo, W. Gu, C. Ricordi, L. Inverardi, and J. Dominguez-Bendala Enhanced Oxygenation Promotes -Cell Differentiation In Vitro Stem Cells, December 1, 2007; 25(12): 3155 - 3164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jiang, M. Au, K. Lu, A. Eshpeter, G. Korbutt, G. Fisk, and A. S. Majumdar Generation of Insulin-Producing Islet-Like Clusters from Human Embryonic Stem Cells Stem Cells, August 1, 2007; 25(8): 1940 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Levenberg, J. Zoldan, Y. Basevitch, and R. Langer Endothelial potential of human embryonic stem cells Blood, August 1, 2007; 110(3): 806 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, D. L. Haviland, A. R. Burns, E. Zsigmond, and R. A. Wetsel A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells PNAS, March 13, 2007; 104(11): 4449 - 4454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lavon, O. Yanuka, and N. Benvenisty The Effect of Overexpression of Pdx1 and Foxa2 on the Differentiation of Human Embryonic Stem Cells into Pancreatic Cells Stem Cells, August 1, 2006; 24(8): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fang, K. Leishear, T. K. Nguyen, R. Finko, K. Cai, M. Fukunaga, L. Li, P. A. Brafford, A. N. Kulp, X. Xu, et al. Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells Stem Cells, July 1, 2006; 24(7): 1668 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Trounson The Production and Directed Differentiation of Human Embryonic Stem Cells Endocr. Rev., April 1, 2006; 27(2): 208 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Priddle, D. R. E. Jones, P. W. Burridge, and R. Patient Hematopoiesis from Human Embryonic Stem Cells: Overcoming the Immune Barrier in Stem Cell Therapies Stem Cells, April 1, 2006; 24(4): 815 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Raikwar, T. Mueller, and N. Zavazava Strategies for Developing Therapeutic Application of Human Embryonic Stem Cells Physiology, February 1, 2006; 21(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hong-mei and C. Gui-an Serum-free medium cultivation to improve efficacy in establishment of human embryonic stem cell lines Hum. Reprod., January 1, 2006; 21(1): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K.C. Brolen, N. Heins, J. Edsbagge, and H. Semb Signals From the Embryonic Mouse Pancreas Induce Differentiation of Human Embryonic Stem Cells Into Insulin-Producing {beta}-Cell-Like Cells Diabetes, October 1, 2005; 54(10): 2867 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yoshida, F. Ishikawa, N. Kawano, K. Shimoda, S. Nagafuchi, S. Shimoda, M. Yasukawa, T. Kanemaru, H. Ishibashi, L. D. Shultz, et al. Human Cord Blood-Derived Cells Generate Insulin-Producing Cells In Vivo Stem Cells, September 1, 2005; 23(9): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Skottman, M. Mikkola, K. Lundin, C. Olsson, A.-M. Stromberg, T. Tuuri, T. Otonkoski, O. Hovatta, and R. Lahesmaa Gene Expression Signatures of Seven Individual Human Embryonic Stem Cell Lines Stem Cells, September 1, 2005; 23(9): 1343 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Soria, F. J. Bedoya, and F. Martin Gastrointestinal Stem Cells I. Pancreatic stem cells Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G177 - G180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Paek, J. R. Morgan, and M. J. Lysaght Sequestration and Synthesis: The Source of Insulin in Cell Clusters Differentiated from Murine Embryonic Stem Cells Stem Cells, August 1, 2005; 23(7): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wobus and K. R. Boheler Embryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy Physiol Rev, April 1, 2005; 85(2): 635 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J Burns, S. J Persaud, and P. M Jones Stem cell therapy for diabetes: do we need to make beta cells? J. Endocrinol., December 1, 2004; 183(3): 437 - 443. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
